Valneva Austria Gmbh

Valneva Se

Dynavax Technologies Corporation

Robert Schlegl

Michael Weber

Jürgen Heindl-Wruss

Mario Nebenführ

Jana Barbero Calzado

Michael Möhlen

Jürgen Wruss

Andreas Meinke

Christoph Reinisch

Benjamin Wizel

Urban Lundberg

Jee Loon Look

Markus Hanner

Karen Lingnau

Wolfgang Schüler

Christoph Klade

Pär Comstedt

Arnaud Leon

Robert Seid

Andrea Fritzer

Brigitte Grohmann

Karin Riedl

Ursula Schlosser

Ljubomir Paucz

Christian Ruiz

Robert S Janssen

David Novack

John Darren Campbell

Urban Lunberg

Christian Taucher

Mario NEBENFÜHR

Wolfgang SCHÜLER

Described herein are processes for purifying infectious virus particles and uses of protamine in such processes.

Virus purification

Described herein are Zika virus vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.

Zika virus vaccine

The present invention relates to a process for producing an immunogenic live attenuated Chikungunya virus, as well as pharmaceutical compositions comprising the same.

Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus CHIKV-delta5NSP3

Described herein are CpG-adjuvanted SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.

CpG-adjuvanted SARS-CoV-2 virus vaccine

Described herein are processes for the purification of viruses and compositions thereof.

Aseptic purification process for viruses

Method of producing pharmaceutical compositions comprising immunogenic Chikungunya virus CHIKV-Delta5nsP3

The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing ainfection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing ainfection and a method of immunizing a subject.

Mutant fragments of OspA and methods and uses relating thereto

Described herein are improved purification methods for Zika virus vaccines and compositions. Also described are Zika vaccines and methods of producing and administering said Zika vaccines to subjects in need thereof.

Zika virus purification

The invention relates to means and methods for preparing aqueous composition comprising aluminium and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminium content. The invention further relates to aqueous compositions comprising a protein and an aluminium-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.

Aluminum compounds for use in therapeutics and vaccines

Described herein are processes for purifying infectious Zika virus particles and uses of protamine in such processes.

Methods for preparing aluminum precipitate compounds for use in therapeutics and vaccines

Growing community of inventors

Siegenfeld, Austria

Robert Schlegl